Losartan Potassium + HydrochlorothiazideThird Party Manufacturing in India

Losartan Potassium and Hydrochlorothiazide is a fixed-dose combination that lowers blood pressure through two complementary mechanisms. Losartan Potassium selectively blocks the angiotensin II type 1 (AT1) receptor, preventing the potent vasoconstrictor and aldosterone-stimulating effects of angiotensin II. This inhibition reduces peripheral vascular resistance, promotes vasodilation, and decreases aldosterone-mediated sodium and water retention. Hydrochlorothiazide, a thiazide diuretic, acts on the distal convoluted tubule of the nephron where it selectively inhibits the sodium-chloride cotransporter on the apical membrane of epithelial cells. By blocking this transporter, hydrochlorothiazide reduces sodium and chloride reabsorption, increasing the urinary excretion of sodium, chloride, and water. This initial diuretic effect reduces plasma volume and cardiac output, while sustained therapy leads to reduced peripheral vascular resistance through mechanisms that may involve direct arteriolar vasodilation and altered vascular reactivity. When losartan and hydrochlorothiazide are used together, their antihypertensive effects are additive. Losartan attenuates the hypokalemia that can occur with hydrochlorothiazide monotherapy, while hydrochlorothiazide enhances blood pressure reduction beyond that achieved at maximal doses of losartan alone. This combination allows for effective blood pressure control at lower individual doses, minimizing dose-related side effects.

Therapeutic Uses

Losartan Potassium + Hydrochlorothiazide combination is prescribed for the management of hypertension:

• Essential Hypertension (Step-Up Therapy): This combination is indicated for patients whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide monotherapy, providing additive antihypertensive effect through complementary mechanisms.
• Stage 2 Hypertension: This combination can be used as initial therapy in patients with more severe hypertension requiring aggressive blood pressure reduction to reach target goals.
• Hypertension with Volume Overload: Patients with hypertension and conditions associated with fluid retention, such as obesity or renal impairment, benefit from the diuretic component of this combination.
• Isolated Systolic Hypertension: The combination is effective in elderly patients with isolated systolic hypertension, where the diuretic component helps reduce systolic blood pressure while the ARB provides vascular protection.

Why Manufacturers Choose Losartan Potassium + Hydrochlorothiazide

This fixed-dose combination is one of the highest-volume antihypertensive products in the Indian pharmaceutical market. It is included in the WHO Essential Medicines List and prescribed widely across all segments of healthcare. The fixed-dose combination offers superior patient compliance compared to separate medications, a significant advantage for PCD franchise marketing. The combination is available in two strengths (50mg+12.5mg and 100mg+25mg), creating a complete product portfolio for franchisees and export partners. Indian manufacturers with WHO-GMP certification and bioequivalence study capabilities are well-positioned to serve both domestic and regulated markets.

This makes Losartan Potassium + Hydrochlorothiazide one of the most sought-after combination products for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.